학술논문
2024 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium.
Document Type
Article
Source
Subject
*KIDNEY tumors
*MEETINGS
*PROFESSIONAL associations
*CONFERENCES & conventions
*PROSTATE tumors
*WEBINARS
BLADDER tumors
GENITOURINARY organ tumors
*
*
*
*
*
Language
ISSN
1911-6470
Abstract
The article highlights the 2024 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium, focusing on recent advancements in genitourinary cancer treatment. Topics discussed include disappointing outcomes of adjuvant nivolumab trials in kidney cancer, promising results from adjuvant pembrolizumab trials, and updates on treatments for bladder cancer, particularly the efficacy of nadofaragene firadenovec in BCG-unresponsive non-muscle-invasive bladder cancer.